Search Results

• • 15 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Immunotherapy for ovarian cancer: what are the targets of the future?

  Authors:Sarah F Adams and Fabian BenenciaFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20152,339 words Editorial 2150LAuthor(s): Sarah F Adams aff1 , Fabian Benencia [*] aff2 KEYWORDS chemotherapy; immunotherapy; ovarian cancer; tumor microenvironment Ovarian cancer Epithelial ovarian cancer affects approximately one in 70...

• Nivolumab: targeting PD-1 to bolster antitumor immunity

  Authors:Julie R Brahmer, Hans Hammers, and Evan J LipsonFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 201512,599 words Report 1780LAuthor(s): Julie R Brahmer [*] aff1 , Hans Hammers aff1 , Evan J Lipson aff1 KEYWORDS immune checkpoint inhibitors; immunotherapy; lung cancer; melanoma; nivolumab; PD-1; programmed death-1; renal cancer The...

• Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study

  Authors:Michele Del Vecchio, Paolo Antonio Ascierto, Mario Mandala, Vanna Chiarion Sileni, Michele Maio, Lorenza Di Guardo, et al.From:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20153,407 words Report 1530LAuthor(s): Michele Del Vecchio [*] aff1 , Paolo Antonio Ascierto aff2 , Mario Mandalà aff3 , Vanna Chiarion Sileni aff4 , Michele Maio aff5 , Lorenza Di Guardo aff1 , Ester Simeone aff2 , Paola Queirolo aff6 KEYWORDS...

• A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas.

  Author:Pierre FeugierFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 201513,034 words Report 1610LABSTRACT Rituximab is a type I anti-CD20 monoclonal antibody, which stabilizes CD20 on lipid rafts, promoting antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. It is the first...

• Human papillomavirus confers radiosensitivity in cancer cervix: a hypothesis toward a possible restoration of apoptotic pathways based on clinical outcomes

  Authors:Niloy Ranjan Datta, Shalini Singh, Piyush Kumar, and Dinesh GuptaFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20155,229 words Report 1540LAuthor(s): Niloy Ranjan Datta [*] aff1 aff2 , Shalini Singh aff1 , Piyush Kumar aff1 aff3 , Dinesh Gupta aff4 KEYWORDS apoptosis; cervical cancer; HPV; p53; pRb; radiation dose-response; radiation therapy;...

• Targeting FGF receptors in colorectal cancer: from bench side to bed side

  Author:Omar Abdel-RahmanFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20154,163 words Report 1810LAuthor(s): Omar Abdel-Rahman [*] KEYWORDS brivanib; FGFR; gastrointestinal cancer; regorafenib Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality worldwide; it is considered as...

• .sup.90Y-glass microspheres for hepatic neoplasia

  Author:Andreas H MahnkenFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20158,743 words Report 1660LAuthor(s): Andreas H Mahnken [*] KEYWORDS HCC; liver; neoplasm; metastasis; radioembolization Primary and secondary liver malignancies are common manifestations of solid tumors. While hepatocellular carcinoma...

• Personalization of loco-regional care for primary breast cancer patients (part 2)

  Authors:Masakazu Toi, Eric P Winer, John R Benson, Takashi Inamoto, John F Forbes, Gunter von Minckwitz, et al.From:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20153,299 words Conference notes, Re... 2000LAuthor(s): Masakazu Toi [*] aff1 , Eric P Winer aff2 , John R Benson aff3 , Takashi Inamoto aff4 , John F Forbes aff5 , Gunter von Minckwitz aff6 , John FR Robertson aff7 , Stephen R Grobmyer aff8 , Ismail Jatoi aff9 ,...

• A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof

  Authors:David M Liu, Avnesh S Thakor, Mark Baerlocher, Mohammed T Alshammari, Howard Lim, Sebastian Kos, et al.From:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20155,464 words Report 1880LAuthor(s): David M Liu [*] aff1 , Avnesh S Thakor aff2 , Mark Baerlocher aff3 , Mohammed T Alshammari aff1 , Howard Lim aff4 , Sebastian Kos aff5 , Andrew S Kennedy aff6 , Harpreet Wasan aff7 KEYWORDS colon cancer...

• Personalization of loco-regional care for primary breast cancer patients (part 1)

  Authors:Masakazu Toi, Eric P Winer, John R Benson, Takashi Inamoto, John F Forbes, Gunter von Minckwitz, et al.From:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20152,638 words Conference notes, Re... 2150LAuthor(s): Masakazu Toi [*] aff1 , Eric P Winer aff2 , John R Benson aff3 , Takashi Inamoto aff4 , John F Forbes aff5 , Gunter von Minckwitz aff6 , John FR Robertson aff7 , Stephen R Grobmyer aff8 , Ismail Jatoi aff9 ,...

• Present and future of personalized medicine in adult genitourinary tumors

  Authors:Chiara Ciccarese, Matteo Santoni, Francesco Massari, Liang Cheng, Antonio Lopez-Beltran, Marina Scarpelli, et al.From:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20155,574 words Report 1940LAuthor(s): Chiara Ciccarese aff1 , Matteo Santoni aff2 , Francesco Massari aff1 , Liang Cheng aff3 , Antonio Lopez-Beltran aff4 , Marina Scarpelli aff5 , Alessandro Conti aff6 , Giampaolo Tortora aff1 , Stefano Cascinu...

• Molecular targets in glioblastoma

  Authors:Maira Zorzan, Enrico Giordan, Marco Redaelli, Antonio Caretta, and Carla Mucignat-CarettaFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 201510,915 words Report 2100LAuthor(s): Maira Zorzan aff1 , Enrico Giordan aff1 , Marco Redaelli aff1 aff2 , Antonio Caretta aff2 aff3 , Carla Mucignat-Caretta [*] aff1 aff2 KEYWORDS diagnosis; glioblastoma; intracellular pathways; signaling;...

• Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice

  Authors:Piergiacomo Calzavara Pinton, Lisa Licitra, Katia Peris, Armando Santoro, and Paolo Antonio AsciertoFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20154,436 words Report 1640LAuthor(s): Piergiacomo Calzavara Pinton aff1 , Lisa Licitra aff2 , Katia Peris aff3 , Armando Santoro aff4 , Paolo Antonio Ascierto [*] aff5 KEYWORDS adverse events; basal cell carcinoma; clinical practice;...

• Molecular pathogenesis of ovarian clear cell carcinoma

  Authors:Ioannis Gounaris and James D BrentonFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 201512,568 words Report 2130LAuthor(s): Ioannis Gounaris [*] aff1 , James D Brenton aff1 KEYWORDS ARID1A; endometriosis; genetically engineered mouse models; glycogen; HNF1B; ovarian clear; PIK3CA cell cancer Origins of epithelial ovarian...

• Kidney cancer and 2014: is innovation really over?

  Authors:Chiara Ciccarese, Alessandra Modena, Giampaolo Tortora, and Francesco MassariFrom:Future Oncology (Vol. 11, Issue 9) Peer-Reviewed

  May 20159,810 words Report 2090LAuthor(s): Chiara Ciccarese aff1 , Alessandra Modena aff1 , Giampaolo Tortora aff1 , Francesco Massari [*] aff1 KEYWORDS metastatic renal cell carcinoma; targeted agents 2014 has certainly been the year of...